GILD

Gilead Sciences, Inc. Press Releases

$89.0563
*  
0.8463
0.96%
Get GILD Alerts
*Delayed - data as of May 2, 2016 15:54 ET  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV
4/29/2016 8:21:00 AM - Business Wire
▼-3.40 % Price Change since this news event. The Volume Ratio is 3.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences Announces Second Quarter 2016 Dividend
4/28/2016 4:02:00 PM - Business Wire
▼-7.72 % Price Change since this news event. The Volume Ratio is 4.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences Announces First Quarter 2016 Financial Results
4/28/2016 4:01:00 PM - Business Wire
▼-5.51 % Price Change since this news event. The Volume Ratio is 4.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV
4/25/2016 7:10:00 AM - Business Wire
▼-12.60 % Price Change since this news event. The Volume Ratio is 2.51.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016
4/21/2016 5:00:00 PM - Business Wire
▼-12.48 % Price Change since this news event. The Volume Ratio is 3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Microsoft trade offers an 8.79% return in 57 days, or find similar option trades on The Goldman Sachs Group, Vmware, Pfizer Inc., and Gilead Sciences
4/21/2016 9:31:00 AM - PR Newswire
▼-11.23 % Price Change since this news event. The Volume Ratio is 1.94.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies
4/16/2016 7:30:00 AM - Business Wire
▼-9.39 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Presents New Data Highlighting Progress in Liver Fibrosis
4/16/2016 6:30:00 AM - Business Wire
▼-9.39 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
4/15/2016 4:30:00 AM - Business Wire
▼-9.29 % Price Change since this news event. The Volume Ratio is 1.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Covered Call Alerts For Kinder Morgan, Pfizer Inc., Caterpillar Inc., Gilead Sciences and Valeant Pharmaceuticals Released By InvestorsObserver
4/13/2016 9:31:00 AM - PR Newswire
▼-8.89 % Price Change since this news event. The Volume Ratio is 1.3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy
4/4/2016 2:57:00 PM - Business Wire
▼-5.66 % Price Change since this news event. The Volume Ratio is 2.49.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases
4/4/2016 8:30:00 AM - Business Wire
▼-5.91 % Price Change since this news event. The Volume Ratio is 1.14.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection
3/31/2016 2:02:00 AM - Business Wire
▼-3.28 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 15
3/10/2016 5:00:00 PM - Business Wire
▲0.40 % Price Change since this news event. The Volume Ratio is 1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016
3/4/2016 6:00:00 PM - Business Wire
▲1.87 % Price Change since this news event. The Volume Ratio is 1.14.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7
3/4/2016 4:00:00 PM - Business Wire
▲2.12 % Price Change since this news event. The Volume Ratio is 1.26.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day